In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.
Su. C M CM; Jensen. L R LR; Heimer. E P EP; Felix. A M AM; Pan. Y C YC; Mowles. T F TF
Key Findings
- Unmodified GRF(1â29)-NH2 is rapidly degraded in plasma (t½ â 13âŻmin), mainly to GRF(3â29)-NH2.
- Cyclizing sideâchains between Asp8 and Lys12 (and optionally also Lys21âAsp25) boosts plasma stability to >2âŻhours.
- Introducing DâAla at positionâŻ2 and/or using a Dâamino acid at the penultimate spot further prolongs the peptideâs halfâlife.
Practical Outcomes
- For biohackers, using GRF analogs that are cyclized or contain Dâamino acids can give a much longer window of action, meaning fewer injections and more stable growthâhormone release. When choosing a GHRH product, look for versions marketed as âcyclicâ or âDâamino acidâmodifiedâ (e.g., CJCâ1295 or customâsynthesized analogs) to take advantage of this increased stability.
Summary
The study shows that the plain growthâhormoneâreleasing factor peptide (GRFâ1â29) disappears from blood very fastâits halfâlife is only about 13 minutes. By swapping a few building blocks or by linking parts of the molecule together (cyclization) and using Dâamino acids, the peptide can stay intact for over two hours. These changes dramatically slow down the breakdown that normally limits how long the peptide works.
Abstract
The stability of growth-hormone releasing factor (growth regulating factor; GRF) analogs in porcine plasma was examined. GRF analogs were incubated in porcine plasma at 37 degrees C, extracted and subsequently analyzed using high performance liquid chromatography (HPLC). GRF(1-29)-NH2 was rapidly broken down in the plasma with a degradation rate of t1/2 = 13 min. The primary degradation product was identified as GRF(3-29)-NH2. Substitution of Gly15 by Ala15 slightly prolonged the plasma half-life (t1/2 = 17 min) and the major degradative fragment was found to be [Ala15]GRF(3-29)-NH2. The cleavage between the 2 and 3 position of the peptide was not inhibited by trasylol at a concentration of 1,000 KIU/ml but was dramatically reduced by the combined use of diprotin A and trasylol. Absence of the free amino group at the N-terminus and/or substitution of a D-amino acid residue at the penultimate position completely prevented cleavage between the 2 and 3 position in the structural linear GRF analogs. Side-chain to side-chain cyclization between Asp8 and Lys12 amino acid residues significantly improved the stability of GRF in plasma with t1/2 greater than 2 hr. An additional stability was provided by substitution of D-Ala2 for Ala2 in the structural cyclic analog. Cyclization between Lys21 and Asp25 also improved the stability of the GRF peptide in the plasma. Stability was further enhanced by the presence of D-Ala2 or by forming a dicyclic analog through an additional linkage between Asp8 and Lys12.
Study Information
pubmed
1991
1991-01-01T00:00:00.000Z
10.1055/s-2007-1003601
24